HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Scribe Therapeutics (NASDAQ:SCTX) with a Buy and maintains $60 price target.
Stocks · News reference
Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate
Scribe Therapeutics (NASDAQ:SCTX) reported quarterly losses of $(2.62) per share which missed the analyst consensus estimate of $(1.05) by 149.52 percent. The company reported quarterly sales of $1.918 million which
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
Scribe Therapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a $60 price target.